WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
| Rodman & Renshaw 19th Annual Global Investment Conference |
| Date: |
Tuesday, September 12 |
| Time: |
9:35 am Eastern Time |
| Location: |
The Lotte New York Palace Hotel, Kennedy I Ballroom |
| Webcast: |
http://wsw.com/webcast/rrshq27/blph |
| |
|
| Ladenburg Thalmann 3rd Annual Healthcare Conference |
| Date: |
Tuesday, September 26 |
| Time: |
1:30 pm Eastern Time |
| Location: |
Sofitel Hotel, New York City, Orleans Ballroom |
| Webcast: |
http://wsw.com/webcast/ladenburg3/blph |
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact
Bellerophon Therapeutics:
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4819
LifeSci AdvisorsBob Yedid, Managing Director
(646) 597-6989
bob@lifesciadvisors.com
Bellerophon Therapeutics Inc.